| Project/Area Number |
25460914
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General internal medicine(including psychosomatic medicine)
|
|---|
| Research Institution | Showa University |
|---|
Principal Investigator |
Iso Yoshitaka 昭和大学, スポーツ運動科学研究所, 准教授 (60384244)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
Suzuki Hiroshi 昭和大学, 医学部, 教授 (90266106)
|
|---|
| Research Collaborator |
Sato Chisato 昭和大学, 大学院医学研究科, 博士課程
Mizukami Takuya 昭和大学, 大学院医学研究科, 博士課程
Sekiya Ichiro 東京医科歯科大学
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 末梢動脈疾患 / 間葉系幹細胞 / 血管新生 / 骨格筋 / エリスロポエチン / FGF-23 |
|---|
| Outline of Final Research Achievements |
Mesenchymal stem cells (MSCs) are present in all adult tissues including bone marrow and skeletal muscle. Aim of this study was to investigate stem cell properties of MSCs from skeletal muscle for development of a novel angiogenic therapy in peripheral artery disease (PAD). Properties of proliferation and differentiation in the MSCs were similar to bone marrow MSCs, whereas pro-angiogenic property in muscle MSCs was superior to the bone marrow cells. The angiogenic potential was activated by erythropoietin. Fibroblast growth factor (FGF)-23 induced cellular senescence of the muscle MSCs via oxidative stress/p53/p21 pathway. PAD is prevalent in patients with chronic kidney disease (CKD). Thus, results of this investigation suggested that disruption of productive balance of those factors in the CKD deteriorated the muscle MSC function. Activation of muscle MSCs via regulation of CKD-related cytokines may become a new therapeutic strategy for PAD.
|
